Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Black Diamond Therapeutic (NASDAQ:BDTX)

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Black Diamond Therapeutic (NASDAQ:BDTX)

Servier Laboratories and Black Diamond Therapeutics Inc. (NASDAQ:BDTX) on Wednesday announced a strategic worldwide licensing agreement for BDTX-4933 for solid tumors. Servier is a pharmaceutical company based in France governed by a non-profit foundation. Under the agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics for RAF/RAS-mutant solid tumors. Under the terms of the deal, Ser…

Black Diamond (NASDAQ: BDTX) Stock Rises on Licensing Deal

Black Diamond Therapeutics (NASDAQ: BDTX) stock rose more than 12% in pre-market trading Thursday after the company inked a significant licensing agreement

#Servier and Black Diamond Therapeutics Forge Global Alliance for BDTX-4933 A New Hope for Patients with RAF/RAS-Mutan...

'SURESNES, France and CAMBRIDGE, Mass., March 19, 2025' '' Servier, an independent global pharmaceutical group guided by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company focusing on MasterKey therapies targeting specific oncogenic mutations, have announced a strategic worldwide licensing agreement for BDTX-4933. This innovative small molecule therapy aims to address significant unmet…

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...